Thus, it would be important to assess the role of HER3 ligands and the effect of HER3 monoclonal antibodies in combination with lapatinib in a larger panel of lapatinib-sensitive and innate-resistant breast cancer cell lines. Here, ERBB3 is linked to breast carcinoma.